Heat Biologics, Inc. HTBX
2.38 +2.38
Day range unavailable
52-week range unavailable
News
globenewswire.com Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing…
globenewswire.com Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics Elusys becomes wholly-owned biodefense subsidiary of NightHawk
globenewswire.com Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.com Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas,…
globenewswire.com REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to…
globenewswire.com Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility 500,000+ square foot facility to support commercial-scale biomanufacturing
globenewswire.com Heat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest Developments DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to…
globenewswire.com Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products New 3-D process…
globenewswire.com Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats Burel to support anthrax and RapidVax™ biodefense initiatives as…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 729 companies set new 52-week lows.
globenewswire.com Heat Biologics Announces Planned Transfer to the NYSE American DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the…
benzinga.com Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax Treatment Elusys Therapeutics Inc, the merger partner for Heat Biologics Inc HTBX, has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S.…
globenewswire.com Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's morning trading, 152 companies set new 52-week lows.
benzinga.com Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110 Heat Biologics Inc (NASDAQ: HTBX) announced promising preclinical data regarding PTX-35. The data has been accepted for publication in the American Journal of Transplantation.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
benzinga.com Heat Biologics To Bolster Presence In Biodefense Space With Elusys Acquisition Heat Biologics Inc (NASDAQ: HTBX) will acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of Anthim (obiltoxaximab) Injection. The acquisition is expected to…
globenewswire.com Heat Biologics Announces Planned Acquisition of Elusys Therapeutics Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S.,…
globenewswire.com Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations
globenewswire.com Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the…
globenewswire.com Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune…
globenewswire.com Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune…
globenewswire.com Heat Biologics to Provide Corporate Update Conference call scheduled for September 2nd at 11:00 AM ET Conference call scheduled for September 2nd at 11:00 AM ET
benzinga.com Heat Biologics Is Starting To Run Away From Support Toward Resistance Heat Biologics Inc. (NASDAQ:HTBX) shares traded higher Thursday morning after the company announced the launch of its wholly-owned subsidiary Skunkworx Bio Inc. focused on developing a drug discovery…
benzinga.com Stocks That Hit 52-Week Highs On Wednesday During Wednesday's morning trading, 254 companies set new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Friday This morning 167 companies reached new 52-week highs.
- benzinga.com 50 Stocks Moving in Thursday's Pre-Market Session Gainers
benzinga.com 31 Stocks Moving in Monday's Pre-Market Session Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 184% to $10.41 in pre-market trading after gaining around 6% on Friday.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday, 225 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Monday Monday's morning session saw 171 companies set new 52-week highs.
benzinga.com 81 Biggest Movers From Friday Gainers
benzinga.com 54 Stocks Moving In Friday's Mid-Day Session Gainers- benzinga.com 85 Biggest Movers From Yesterday
benzinga.com 50 Stocks Moving In Tuesday's Mid-Day Session - benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday
- benzinga.com Stocks That Hit 52-Week Lows On Monday
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks That Hit 52-Week Lows Of Monday
- benzinga.com List of Companies Reaching Yearly Lows Tuesday
- benzinga.com 50 Biggest Movers From Wednesday
- benzinga.com 34 Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com 42 Biggest Movers From Yesterday
- benzinga.com 41 Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Mid-Afternoon Market Update: Community Health Systems Surges Following Q1 Beat; TC PipeLines Shares Slide
- benzinga.com Mid-Day Market Update: Nanometrics Rises On Earnings Beat; Esperion Therapeutics Shares Drop
benzinga.com Benzinga Pro's Most-Searched Tickers For Afternoon Of May 1, 2018 - benzinga.com 10 Biggest Mid-Day Gainers For Tuesday